News

Details

Published: 26 May 2020

• portfolio-news

Themis and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.

Details

Published: 14 May 2020

• portfolio-news

Themis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an agreement under which ABL will manufacture Themis’ vaccine candidate in preparation for clinical trials. The vaccine is being developed using a proprietary measles virus vaccine platform technology, which is licensed exclusively to Themis by the world-renowned Institut Pasteur in Paris.

Details

Published: 27 April 2020

• portfolio-news

Mr. Hovard, who will serve as the Company’s first independent Director, brings more than 20 years of leadership in the medical device and urology industry. Over the last 20 years, Mr. Hovard has held multiple leadership roles at subsidiaries of Coloplast, a publicly-traded global medical device company. Most recently, he served as the President of Interventional Urology from 2011 to 2019.